Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression

Immunology Letters

Volumn 114, Issue 1, 2007, Pages 46-51

  Motta, M ^b   Imbesi, R ^a   Di Rosa, M ^a   Stivala, F ^a   Malaguarnera, L ^a  

^a Department of Biomedical Sciences ^*  (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alzheimer's disease; Immune response; Interleukin 12; Interleukin 16; Interleukin 18; Transforming growth factor beta 1

Indexed keywords

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 18; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; TRANSFORMING GROWTH FACTOR BETA1;

EID: 35448979876     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.09.002     Document Type: Article

References (43)

1. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J Neuroimmunol 103 (2000) 97-102
2. McGeer P.L., and McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21 (1995) 195-218
3. Lombardi V.R., Garcia M., RevL, and Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease (AD) individuals. J Neuroimmunol 97 (1999) 163-171
4. Zetterberg H., Andreasen N., and Blennow K. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. Neurosci Lett 367 (2004) 194-196
5. Tarkowski E., Andreasen N., Tarkowski A., and Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 74 (2003) 1200-1205
6. Tarkowski E., Issa R., Sjogren M., Wallin A., Blennow K., Tarkowski A., et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 23 (2002) 237-243
7. Mocali A., Cedrola S., Della Malva N., Bontempelli M., Mitidieri V.A., Bavazzano A., et al. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol 39 (2004) 1555-1561
8. De Servi B., La Porta C.A., Bontempelli M., and Comolli R. Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease. Exp Gerontol 37 (2002) 813-821
9. Storkus W.J., Tahara H., and Lotze M.T. Interleukin-12. In: Thomson A. (Ed). The cytokine handbook (1998), Academic Press, San Diego 390-425
10. Rentzos M., Paraskevas G.P., Kapaki E., Nikolaou C., Zoga M., Rombos A., et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J Neurol Sci 249 (2006) 110-114
11. Mathy N.L., Bannert N., Norley S.G., and Kurth R. Cutting edge: CD4 is not required for the functional activity of IL-16. J Immunol 164 (2000) 4429-4432
12. Lipton P. Ischemic cell death in brain. Neurons Physiol Rev 79 (1999) 1431-1568
13. Okamura H., Tsutsui H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378 (1995) 88-91
14. Lebel-Binay S., Berger A., Zinzindohoue F., Cugnenc P., Thiounn N., Fridman W.H., et al. Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 11 (2000) 15-26
15. Wheeler R.D., Culhane A.C., Hall M.D., Pickering-Brown S., Rothwell N.J., and Luheshi G.N. Detection of the interleukin 18 family in rat brain by RT-PCR. Brain Res Mol Brain Res 77 (2000) 290-293
16. Conti B., Park L.C., Calingasan N.Y., Kim Y., Kim H., Bae Y., et al. Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res 67 (1999) 46-52
17. Sugama S., Wirz S.A., Barr A.M., Conti B., Bartfai T., and Shibasaki T. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. Neuroscience 128 (2004) 451-458
18. Lawrence D.A. Transforming growth factor-beta: a general review. Eur Cytokine Netw 7 (1996) 363-374
19. Wyss-Coray T., Masliah E., Mallory M., McConlogue L., Johnson-Wood K., Lin C., et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 389 (1997) 603-606
20. Lesne S., Docagne F., Gabriel C., Liot G., Lahiri D.K., Buee L., et al. Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem 278 (2003) 18408-18418
21. Lacombe P., Mathews P.M., Schmidt S.D., Breidert T., Heneka M.T., Landreth G.E., et al. Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised. J Neuroinflamm 1 (2004) 1-11
22. Di Rosa M., Dell'Ombra N., Zambito A.M., Malaguarnera M., Nicoletti F., and Malaguarnera L. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia. Eur J Neurosci 23 (2006) 2648-2656
23. Dick J.P., Guiloff R.J., Stewart A., Blackstock J., Bielawska C., Paul E.A., et al. Mini-mental state examination in neurological patients. J Neurol Neurosurg Psychiatry 47 (1984) 496-499
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
25. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
26. Hachinski V.C., Iliff L.D., Zilhka E., Du Boulay G.H., McAllister V.L., Marshall J., et al. Cerebral blood flow in dementia. Arch Neurol 32 (1975) 632-637
27. Reale M., Iarlori C., Gambi F., Feliciani C., Salone A., Toma L., et al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol 148 (2004) 162-171
28. Schluesener H.J., Seid K., Kretzschmar J., and Meyermann R. Leukocyte chemotactic factor, a natural ligand to CD4, is expressed by lymphocytes and microglial cells of the MS plaque. J Neurosci Res 44 (1996) 606-611
29. Schwab J.M., Nguyen T.D., Meyermann R., and Schluesener H.J. Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages. J Neuroimmunol 114 (2001) 232-241
30. Wheeler R.D., Brough D., Le Feuvre R.A., Takeda K., Iwakura Y., Luheshi G.N., et al. Interleukin-18 induces expression and release of cytokines from murine glial cells: interactions with interleukin-1β. J Neurochem 85 (2003) 1412-1420
31. Lindberg C., Eriksson C., Van Dam A.M., Winblad B., and Schultzberg M. Neuronal expression of caspase-1 immunoreactivity in the rat central nervous system. J Neuroimmunol 146 (2004) 99-113
32. Suk K., Yeou Kim S., and Kim H. Regulation of IL-18 production by IFN-γ and PGE2 in mouse microglial cells: involvement of NF-κB pathway in the regulatory processes. Immunol Lett 77 (2001) 79-85
33. Chandrasekar B., Valente A.J., Freeman G.L., Mahimainathan L., and Mummidi S. Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-kappa B-dependent PTEN activation. Biochem Biophys Res Commun 339 (2006) 956-963
34. Konig H.G., Kogel D., Rami A., and Prehn J.H. TGF-{beta}1 activates two distinct type I receptors in neurons: implications for neuronal NF-κB signaling. J Cell Biol 168 (2005) 1077-1086
35. Luterman J.D., Haroutunian V., Yemul S., Ho L., Purohit D., Aisen P.S., et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 57 (2000) 1153-1160
36. van der Wal E.A.F., Gomez-Pinilla F., and Cotmann C.W. Transforming growth factor-beta 1 is in plaques in Alzheimer and down pathologies. Neuroreport 4 (1993) 69-72
37. Malaguarnera L., Motta M., Di Rosa M., Anzaldi M., and Malaguarnera M. Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia. Neuropathology 26 (2006) 307-312
38. Panossian L.A., Porter V.R., Valenzuela H.F., Zhu X., Reback E., and Masterman D. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging 24 (2003) 77-84
39. Mecocci P., Polidori M.C., Ingegni T., Cherubini A., Chionne F., Cecchetti R., et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology 51 (1998) 1014-1017
40. Sulger J., Dumais-Huber C., Zerfass R., Henn F.A., and Aldenhoff J.B. The calcium response of human T lymphocytes is decreased in aging but increased in Alzheimer's dementia. Biol Psychiatry 15 (1999) 737-742
41. Trieb K., Ransmayr G., Sgonc R., Lassmann H., and Grubeck-Loebenstein B. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging 17 (1996) 541-547
42. Giubilei F., Antonimi G., Montesperelli C., Sepe-Monti M., Cannoni S., Pichi A., et al. T cell response to amyloid-beta and to mitochondrial antigens in Alzheimer's disease. Dement Geriatr Cogn Disord 16 (2003) 35-38
43. Albert S.M., Costa R., Merchant C., Small S., Jenders R.A., and Stern Y. Hospitalization and Alzheimer's disease: results from a community-based study. J Gerontol A Biol Sci Med Sci 54 (1999) M267-M271